CEO of Arrowhead Pharmaceuticals Inc (30-Year Financial, Insider Trades) Christopher Richard Anzalone (insider trades) sold 112,650 shares of ARWR on 09/24/2019 at an average price of $28.54 a share. The total sale was $3.2 million.
Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins. Arrowhead Pharmaceuticals Inc has a market cap of $2.68 billion; its shares were traded at around $28.08 with a P/E ratio of 61.02 and P/S ratio of 19.85. Arrowhead Pharmaceuticals Inc had annual average EBITDA growth of 17.50% over the past ten years. GuruFocus has detected 1 severe warning sign with Arrowhead Pharmaceuticals Inc. .
CEO Recent Trades:
- CEO Christopher Richard Anzalone sold 112,650 shares of ARWR stock on 09/24/2019 at the average price of $28.54. The price of the stock has decreased by 1.61% since.
Directors and Officers Recent Trades:
- Director Michael S Perry sold 185,000 shares of ARWR stock on 09/11/2019 at the average price of $29.41. The price of the stock has decreased by 4.52% since.
For the complete insider trading history of ARWR, click here
.
